JOINT &
MOBILITY JOURNAL

THE EVIDENCE FOR
MOVING WELL.

Red Globe, a variety of very large, seeded red grapes, captured in West Bengal, India; photo taken by Yogabrata Chakraborty, on October 1, 2022.
Red Globe, a variety of very large, seeded red grapes, captured in West Bengal, India · Billjones94 · CC BY-SA 4.0 · Source · License
Joint Support / EVIDENCE GUIDE

Resveratrol for knee osteoarthritis: a phase 3 trial found no pain benefit

A multicenter phase 3 trial found resveratrol no better than placebo for knee pain, despite favorable signals in another frailty-focused study.

THE KEY TAKEAWAY

The strongest direct pain trial was negative, so resveratrol should not be promoted as established knee-osteoarthritis relief.

Red-wine biology does not predict capsule results

Resveratrol is a polyphenol found in grapes, berries and red wine. Laboratory research has explored anti-inflammatory and metabolic pathways, creating interest in osteoarthritis. Concentrated supplements deliver exposure unlike food, and drinking wine is not a tested substitute for a capsule.

The clinical question is straightforward: does a characterized oral product reduce pain or improve function more than placebo? Mechanisms and biomarkers remain secondary unless a patient-important outcome changes.

Vitis vinifera (Grape) Fruit at Kihei, Maui, Hawaii. August 14, 2009 #090814-4400 Image Use Policy
Starr-090814-4400-Vitis vinifera-fruit-Kihei-Maui (24341806064) · Forest and Kim Starr · CC BY 3.0 us · Source · License

The ARTHROL trial directly tested knee pain

The multicenter double-blind phase 3 ARTHROL trial randomized 142 adults with painful knee osteoarthritis to a patented oral resveratrol formulation or placebo for six months. At three months, pain fell by about fifteen points in both groups. The between-group difference was nearly zero and not statistically significant.

The investigators acknowledged that recruitment fell short of the planned power and the expected effect was optimistic. Even so, the observed estimate did not suggest a clinically useful separation. Calling the study merely inconclusive would understate how similar the groups were.

A newer frailty-focused trial was favorable

A separate 16-week trial in 123 older adults with knee osteoarthritis reported improvements in frailty, walking pain, WOMAC, Oxford knee scores and handgrip strength with 500 milligrams of resveratrol daily. Range of motion and gait speed did not improve.

Differences in dose, formulation, population, outcomes and trial conduct may explain the contrasting results. One positive study does not erase a well-controlled negative phase 3 pain trial. Replication is needed before identifying a responsive subgroup.

Biomarker changes do not settle the conflict

The frailty trial reported higher SIRT1 levels associated with frailty scores. That finding may inform mechanism research, but it does not prove SIRT1 caused the clinical changes. Biomarker-outcome correlations inside a trial can reflect several shared influences.

A seller should not use SIRT1 language to imply cartilage repair or longevity benefits. Those are separate claims requiring separate evidence. The measured outcomes and study duration should define the conclusion.

Fitness stairs of Möskäri in Simonkylä, Vantaa, Finland in 2021 July.
Fitness stairs of Möskäri in Simonkylä, Vantaa, Finland, 2021 July · Ximonic (Simo Räsänen) · CC BY 3.0 · Source · License

Product and interaction questions remain

Resveratrol supplements differ in purity, trans-resveratrol content, formulation and amount. A patented formulation may not match a generic product. High doses can cause gastrointestinal symptoms and may affect bleeding or drug metabolism.

People taking anticoagulants, antiplatelet medicines or several supplements should review the complete regimen. Wine imagery should not be used to imply cardiovascular or joint benefit from alcohol, which carries independent health risks.

The strongest claim is a negative one

Current evidence does not establish resveratrol as effective knee-osteoarthritis pain treatment. A large direct trial found no added pain benefit, while a newer study generated a potentially interesting but unconfirmed frailty signal. That mixed record should be visible in product reporting.

Future trials should replicate the positive protocol, characterize products and prespecify whether pain, function or frailty is primary. Until then, consumers should not replace supported care with a polyphenol narrative or assume that more concentrated exposure produces more benefit.

Why the placebo response deserves attention

In ARTHROL, both groups experienced similar pain reduction. That does not mean the participants’ improvement was imaginary. Clinical attention, continued background care, regression toward average symptoms and expectations can all change reported pain. Randomization asks whether resveratrol adds something beyond those shared influences; in this trial, it did not.

This is why advertisements that show only the supplement group’s before-and-after score are incomplete. The placebo trajectory is part of the result. A future positive trial would need a clear between-group difference, not merely improvement after treatment. It should also report the proportion reaching a patient-important threshold rather than relying only on an average.

The negative phase 3 result also limits dose speculation. It is tempting to argue that a different amount must work, but dose-response claims need trials rather than hindsight. Higher exposure may increase gastrointestinal or interaction risks without improving pain. The appropriate next step is a well-justified protocol that explains why another formulation or population could differ, not a retail recommendation to keep escalating until an effect is felt.

Sources & further reading

  1. Oral resveratrol in adults with knee osteoarthritis: ARTHROL randomized placebo-controlled phase 3 trial ↗
  2. Resveratrol, SIRT1 and frailty phenotype in knee osteoarthritis: randomized placebo-controlled trial ↗
  3. Efficacy and Safety of Polyphenols for Osteoarthritis Treatment: meta-analysis ↗

This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.

More on Joint Support →